Stocksigma LogoStocksigma Logo

Biocon Secures Earliest Global Launch Dates for Biosimilar Pertuzumab via Genentech Settlement

Biocon Limited has entered into a global settlement and licensing agreement with Genentech to resolve all pending patent disputes across the U.S., Canada

Biocon Secures Earliest Global Launch Dates for Biosimilar Pertuzumab via Genentech Settlement

Biocon Ltd 路 Others (Uncategorized) 路 14 Oct 2026, 1:55 pm

Biocon Secures Earliest Global Launch Dates for Biosimilar Pertuzumab via Genentech Settlement Biocon Limited has entered into a global settlement and licensing agreement with Genentech to resolve all pending patent disputes across the U.S., Canada, and other jurisdictions. The agreement secures earliest licensed launch dates for Pebrilzo, a biosimilar referencing Perjeta (Pertuzumab) for HER2-positive breast cancer. Biocon is licensed to launch Pebrilzo in the EU and UK in Q1 CY'27, the U.S. in Q3 CY'28, and Rest of the World markets across CY'26鈥揅Y'28, subject to regulatory approvals. Other financial terms remain confidential.

Original exchange filing (PDF)

More announcements from Biocon Ltd

All Biocon Ltd announcements